Patients with the antiphospholipid syndrome (APS) suffer a thrombophilic condition characterized by multiple defects such as acquired deficiencies of protein C (PC), protein S (PS), and antithrombin III (AT III) (1); impaired fibrinolysis (2) ; increased levels of lipoprotein (a) (3); vasculopathy (4) ; activated PC resistance (5-7), etc. Some, but not all, of these changes have been related to the presence of antiphospholipid antibodies (APA), lupus anticoagulants (LAs), and autoantibodies directed towards PC (8) ; PS (9) ; AT III (10), tissue-type plasminogen activator (11) , thrombomodulin (12) , and other phospholipid-binding plasma proteins (13) . The APS may be associated with systemic lupus erythematosus (14) (15) or have no associated condition (primary APS) (16) (17) .
In recent years, the study of the molecular basis of thrombophilia has changed considerably by the identification of two alleles that are associated with an increased risk of venous thrombosis: the factor V 1691 A allele (factor V Leiden allele) (18, 19) and the prothrombin 20210 A allele (20) . Both alleles are common in the general white population (8% and 2%, respectively) (21, 22) ; but are uncommon in Amerindians and American mestizos (23) (24) (25) .
The prevalence of the factor V 1691 A allele (factor V Leiden allele) in patients with the antiphospholipid syndrome is not higher than that found in the general population (5) (6) (7) (26) (27) (28) , whereas the prevalence of the prothrombin 20210 A allele in this population is unknown. We describe here the results of looking for the G20210A polymorphism in the 3'-untranslated region of the prothrombin gene in a group of 14 patients with primary APS.
MATERIAL AND METHODS

Samples .
Deoxyribonucleic acid (DNA), purified by standard procedures (29) from blood samples from 14 patients with primary APS who were diagnosed according to previously published criteria (16, 17) , was studied. In the absence of an overt autoimmune disease and in the presence of high titers of antiphospholipid antibodies, all patients had one of the following symptoms: deep vein thrombosis, arterial occlusions, pulmonary embolism, stroke, fetal loss, thrombocytopenia, or autoimmune hemolytic anemia. In addition, samples of 25 patients with a history of thrombophilia (24) without APS were also studied. All of them had a history of venous or arterial occlusive episodes. mM each primer, 1 U Taq DNA polymerase, 0.1-0.5 mg sample DNA). One of the primers introduces a mutation that together with the G ~ A mutation generates a Hind III restriction site. An aliquot of 4 mL of the amplified product was therefore subjected to digestion with the restriction endonuclease Hind III. The restriction pattern was analyzed by electrophoresis on a 4.5% polyacrylamide gel.
RESULTS
The study of all the DNA samples of patients with primary APS rendered normal results when looking for the G20210A polymorphism in the 3'-untranslated region of the prothrombin gene (Table 1 and Fig. 1 ). Two of 25 Mexican mestizo patients with non-APS thrombophilia were found to be heterozygous for the G-A mutation at nucleotide position 20210 of the prothrombin gene.
DISCUSSION
We have been interested in assessing the thrombophilic conditions, inherited or acquired, that could have a relation with the thrombophilia observed in patients with APS (30) . Concerning the common risk alleles for venous thrombosis, we have previously reported the factor V Leiden mutation in 1 of 22 Mexican mestizo patients with primary APS (5) , this ratio is not significantly higher than that reported in the general population in Mexico (24, 25) . It is interesting that higher prevalences of the factor V Leiden mutation leading into activated protein C (APC) resistance in patients with APS have been reported in places with a higher prevalence of the R506Q factor V gene mutation (31) . A heterogeneous ethnic and geographic distribution has been reported for three genetic risk factor for thrombosis: factor V Leiden, the 677 C ~ T mutation in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene (which is associated with hyperhomocystinemia), and the G ~ A mutation at nucleotide position 20210 in the 3'-untranslated region of the prothrombin gene (21) (22) 32) .
The APC resistance phenotype has been found in patients with APS. Up to 93% of patients with LA and recurrent thrombosis were found to display functional APC resistance although the factor V Leiden mutation in their patients was not tested (33) . Other authors have also found the APC resistance phenotype in the absence of the factor V Leiden mutation in thrombophilic patients with APS (5, 7, 34) , and it has been shown that the phenotype may even follow a relapsing course over time (35) . However, the hyperhomocystinemia phenotype has also been shown in thrombophilic patients with systemic lupus erythematosus, irrespective of the 677 C ~ T mutation in the 5,10-MTHFR gene (36) . Since the study in the group of patients in this report was performed in samples of a DNA bank, the prothrombin levels were not assessed. However, in previous studies we have not found hyperprothrombinemia associated with thrombophilia in patients with APS. In this group of patients we had previously assessed the factor V Leiden mutation, which was found in one patient (5) . Consonant with these findings, there is data that suggest that the thrombophilia of patients with primary APS is not related with the Go A mutation at nucleotide position 20210 in the 3'untranslated region of the prothrombin gene (37) . weight marker (pUC-18 digested with Hpa II); P, patient sample; GA and GG, control DNAs heterozygous and homozygous normal, respectively.
In summary, we have not found the G20210A polymorphism in the 3'-untranslated region of the prothrombin gene in a group of 14 patients with primary APS. Since the prothrombin mutation is more prevalent in white populations, this finding may be related to the genetic composition of the Mexican mestizos: 56% Indian genes, 40% of white genes, and 4% black genes (38) . Despite the low number of cases, it seems that the polymorphism of the prothrombin gene in Mexican mestizo patients with antiphospholipid syndrome is not related to the thrombophilia observed in these patients.
